Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners by Abdalla, M.I. et al.
Prevalence and Impact of Inflammatory Bowel Disease–Irritable
Bowel Syndrome on Patient-reportedOutcomes in CCFA Partners
Maisa I. Abdalla, MD, MPH,*,† Robert S. Sandler, MD, MPH,* Michael D. Kappelman, MD, MPH,‡
Christopher F. Martin, MSPH,* Wenli Chen, MA, MS,* Kristen Anton, MS,§ and Millie D. Long, MD, MPH*
Background: Inflammatory bowel disease (IBD) patients with persistent symptoms despite no or minimal inflammation are frequently described as
having an overlap of IBD and irritable bowel syndrome (IBD–IBS). Limited data are available on how IBS impacts the individual patient with IBD. In
this study, we aimed to evaluate the prevalence of IBD–IBS and investigate its impact on patient-reported outcomes.
Method: We performed a cross-sectional analysis within the CCFA Partners Study. Bivariate analyses and logistic regression models were used to
investigate associations between IBD–IBS and various demographic, disease factors, and patient-reported outcomes including anxiety, depression, sleep
disturbances, pain interference, and social satisfaction.
Results: Of the 6309 participants included, a total of 1279 (20%) reported a coexisting IBS diagnosis. The prevalence of IBD–IBS in this cohort was
similar within disease subtypes. A diagnosis of IBD–IBS was associated with higher narcotic use compared with those with no IBS diagnosis for both
Crohn’s disease, 17% versus 11% (P , 0.001) and ulcerative colitis/indeterminate colitis, 9% versus 5% (P , 0.001). Quality of life, as measured by
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was lower in patients with IBD–IBS compared with those without. IBD–IBS diagnosis was
associated with anxiety, depression, fatigue, sleep disturbances, pain interference, and decreased social satisfaction.
Conclusions: In this sample of patients with IBD, high prevalence of concomitant IBS diagnosis was observed. IBD–IBS diagnosis was associated with
increased narcotic use and adverse patient-reported outcome. Appropriate diagnosis, treatment, and counseling may help improve the functional status of
IBD–IBS patients and decrease narcotic use.
(Inflamm Bowel Dis 2017;23:325–331)
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M any patients with inflammatory bowel disease (IBD) con-tinue to experience symptoms of abdominal pain and
diarrhea despite minimal or no active inflammation. These pa-
tients are frequently described as having an overlap between
IBD and irritable bowel syndrome (IBD–IBS). The awareness
of IBD–IBS has increased over time as several studies have
reported a higher prevalence of IBS among patients with IBD
compared with the general population.1–5 In a meta-analysis by
Halpin et al,6 pooled data from 13 studies revealed an overall
prevalence of IBS of 35% in patients with IBD who were in
apparent remission.
Less is known about the impact of IBS on the individual
IBD patient’s care and functional status. IBS has been linked to
disproportionate excessive health care utilization with total direct
and indirect annual expenditures exceeding $20 billion.7,8 How-
ever, it remains unclear what additional health burden it may
inflict on patients with IBD. In a study by Ramos-Rivers et al,9
patients with IBD who were higher users of health resources,
namely telephone encounters, were more likely to have chronic
abdominal pain and psychiatric comorbidities, both features fre-
quently seen in patients with IBS. Furthermore, it is often difficult
to clinically differentiate between symptoms of IBS and those of
active inflammation. Hence, patients with IBD–IBS may unnec-
essarily undergo repeated gastrointestinal (GI) procedures and
abdominal imaging, have unnecessary escalation of immunosup-
pressive therapies, or a delay in initiating needed therapies. IBD–
IBS may also impact medication utilization, particularly rates of
narcotic use, which have been shown to be higher for IBD pa-
tients with concomitant IBS diagnosis compared with those with-
out IBS in inpatient settings.10
Although both IBD and IBS have been independently
linked to reduced health-related quality of life (HRQOL)
measures and have been associated with several psychiatric
comorbidities, such as depression, anxiety, fatigue, and sleep
Received for publication September 16, 2016; Accepted December 1, 2016.
From the *Department of Medicine, Division of Gastroenterology and Hepatol-
ogy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;
†Department of Medicine, Division of Gastroenterology and Hepatology, Loma
Linda University, Loma Linda, California; ‡Department of Pediatrics. Division of
Pediatric Gastroenterology, University of North Carolina, Chapel Hill, North
Carolina; and §Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Supported by the Crohn’s and Colitis Foundation of America, Patient Centered
Outcomes Research Institute, NIH P30 DK34987 and NIH 1K08DK088957-01.
M. D. Long has consulted for Abbvie, Salix, Pfizer and Theravance
pharmaceuticals. M. D. Kappelman has consulted for Abbvie, Janssen, and
GlaxoSmithKline. The remaining authors have no conflict of interest to disclose.
Address correspondence to: Maisa I. Abdalla, MD, MPH, Department of
Medicine, Division of Gastroenterology and Hepatology, 11234 Anderson Street,
MC 1556, Loma Linda, CA 92354 (e-mail: misaabdalla@gmail.com).
DOI 10.1097/MIB.0000000000001017
Published online 13 January 2017.
each of the PROMIS measures. The items are then calibrated using
T-score metric to provide a mean value for the measure assessed. In
the general US population, the mean for each domain is 50 with
a SD of 10. A priori thresholds of $52 (anxiety, depression,
fatigue, pain interference, and sleep disturbances) and #48 (social
satisfaction) were selected to define the presence of adverse PRO
within each measure. We have chosen these threshold points to
allow for a clinically meaningful separation from the general pop-
ulation. Minimal important differences in PROMIS measures for
patients with IBD have not been defined. However, research in
patients with cancer, patients with chronic pain, and healthy pedi-
atric population revealed a range of minimal important differences
of 2 to 6 for several of the PROMIS measures.23–25 Numbers of
clinic visits to the primary care physician (PCP) and GI physician
within the previous year were used as indicators for health care
utilization. High utilization was defined by $5 visits to the PCP or
GI physician within the previous year.
Statistical Analysis
We first performed bivariate analyses to evaluate associa-
tions between IBD–IBS and the various demographic and disease-
related variables stratified by disease subtypes. Continuous
variables were presented as means and SD, whereas the categor-
ical variables were reported as percentages. Comparisons were
made using Pearson’s chi-square test for categorical variables
and Student’s t test or Mann–Whitney test for continuous varia-
bles. Logistic regression models were then used to investigate
independent associations between IBD–IBS and each of the 6
PROs while controlling for participants’ age, body mass index,
disease subtype, disease duration, sex, narcotics use, smoking
status, and IBD therapies. All statistical analyses were performed
using SPSS version 22.0 (IBM Corp., Armonk, NY).
Ethical Considerations
The study protocol was approved by the Institutional
Review Board at the University of North Carolina.
RESULTS
Study Population
A total of 6309 participants met the inclusion criteria for the
study. Of these, 3947 reported having CD and 2362 reported UC
or IC. Most participants were women (71.9%) and whites
(94.1%). The mean age of the study cohort was 44 years, and
the average time between the initial diagnosis and the time of the
survey completion was 14 years.
A total of 1279 (20.3%) participants reported a coexisting
IBS diagnosis. The proportion of patients reporting concomitant
IBS diagnosis was similar among patients with CD (20.0%) and
UC/IC (20.7%) P ¼ 0.49. In both CD and UC/IC groups, patients
with IBD–IBS were more likely to be women and have higher
body mass index and were less likely to have graduated college,
as compared with those with no concomitant IBS diagnosis
(Table 1). In UC/IC group, the mean age for patients with
disturbances, little is known about the impact of combined IBD 
and IBS on patients’ functional status.11,12 Few studies have con-
sistently shown reduced HRQOL scores in patients with IBD–IBS 
compared with IBD patients with no concomitant IBS diagnosis. 
However, variable results were seen in regard to associations with 
anxiety and depression.2–4,13–19 These studies included a relatively 
small number of patients (range: 50–276), and varied in their 
inclusion criteria and the instruments used to assess the different 
aspects of a patients’ functional status. We therefore aimed to 
evaluate the epidemiologic and disease-related characteristics of 
patients with IBD–IBS within a large sample of patients with 
IBD. In addition, we aimed to investigate the impact of this diag-
nosis on various patient-reported outcomes (PROs), including 
measures of functional status, and specific medication utilization.
MATERIALS AND METHODS
Study Design
We performed a cross-sectional analysis of a subset of 
patients within the Crohn’s and Colitis Foundation of America 
(CCFA) Partners cohort.
Study Population
CCFA Partners is a longitudinal internet-based cohort of 
adult patients with IBD, which has been ongoing since 2011. The 
development of the cohort was previously described.20 In brief, 
after a baseline survey, participants are invited to complete 
follow-up surveys every 6 months. At baseline and every 
follow-up interval, data on demographics, disease subtype and 
characteristics, medications, measures of disease activity, and var-
ious PROs are collected. All data are self-reported.
In 2014, the surveys were updated to include the following 
question: “After you were diagnosed with IBD has a doctor ever 
told you that you had Irritable Bowel Syndrome (IBS)?” with 3 
possible answers: (1) Yes, (2) No, or (3) Don’t know. Participants 
who answered this question with either yes or no were included in 
this analysis (n ¼ 6309).
Study Variables
Disease activity was assessed using short Crohn’s Disease  
Activity Index (sCDAI) for Crohn’s disease (CD) and Simple Clin-
ical Colitis Activity Index (SCCAI) for ulcerative colitis (UC)/
indeterminate colitis (IC). Active disease was defined as sCDAI
$150 for CD and SCCAI .2 for UC/IC. The short IBD Question-
naire (SIBDQ) (Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) was authored by Dr. J. Irvine, et al, was made under 
license from McMaster University, Hamilton, Canada) was used 
to assess HRQOL. For each participant, levels of anxiety, depres-
sion, fatigue, sleep disturbances, pain interference, and social sat-
isfaction were assessed using the Patient-Reported Outcomes 
Measurement Information System (PROMIS). The PROMIS meas-
ures have been previously validated in general and chronically ill 
populations and their performance was assessed within the CCFA 
Partners cohort.11,21,22 In brief, participants completed 4 items for
IBD–IBS was significantly higher compared with those with no
IBS diagnosis (47 versus 43, respectively, P ¼ ,0.001). No
significant age differences were noted between the 2 groups in
patients with CD. The proportion of patients with at least one
previous abdominal surgery was lower in patients with IBD–IBS
compared with those with no IBS diagnosis in both CD and UC/
IC participants. Patients with IBD–IBS had lower rates of current
ileal/Kock pouch and current ostomy compared with those with
no IBS diagnosis in UC/IC and CD groups, respectively. In both
CD and UC/IC groups, patients with IBD–IBS were more likely
to have a sCDAI score $150 (CD) or SCCAI .2 (UC/IC) com-
pared with those with no concomitant IBS (48.9% versus 34.8%
[CD] and 63.7% versus 48.3% [UC/IC]).
Health Resources and Medications Utilization
In both CD and UC/IC, patients with concomitant IBS
diagnosis were more likely to report $5 visits to their PCP and GI
physician within the previous year compared with those with no
concomitant IBS diagnosis (Table 2). Furthermore, using logistic
regression models to assess the impact of IBD–IBS diagnosis on
the likelihood that participants would report $5 visits to their PCP
and GI physicians within the previous year while controlling for age,
sex, disease subtype, current narcotics use, and current use of various
IBD therapies, IBD–IBS was an independent predictor for both out-
comes (odds ratio [OR] 1.76, 95% confidence interval [CI], 1.45–2.14
for PCP visits and for GI visits, OR 1.36, 95% CI, 1.13–1.64.
Participants with IBD–IBS diagnosis were more likely to
report current narcotic use compared with those with no IBS
diagnosis, in both disease subtypes (Fig. 1). Among patients in
clinical remission (defined by sCDAI score ,150 for CD and
SCCAI #2 for UC/IC), higher rates of narcotic use among
patients with IBD–IBS were still observed in both CD (7.2%)
and UC/IC (4.7%). No significant differences were seen in regard
to IBD therapies (5-aminosalicylates, immunomodulators, and bi-
ologics) utilization between patients with IBD–IBS and those with
no concomitant IBS diagnosis in both disease subtypes. In addi-
tion, IBD–IBS diagnosis was not associated with higher rates of
current corticosteroids use (Table 2).
Impact on Quality of Life and PROs
On bivariate analyses stratified by disease activity, patients
with IBD–IBS had lower SIBDQ scores compared with those
with no concomitant IBS diagnosis. The difference was signifi-
cant for both disease subtypes (Table 3). Furthermore, patients
with IBD–IBS had significantly higher mean values for anxiety,
depression, fatigue, pain interference, and sleep disturbances and
lower social satisfaction means compared with those with no
concomitant IBS diagnosis in both disease subtypes (Table 3).
Using logistic regression models to investigate independent asso-
ciations between IBD–IBS and the presence of each of the 6
PROs, IBD–IBS was an independent predictor for anxiety (OR
1.62, 95% CI, 1.41–1.87), depression (OR 1.59, 95% CI,
1.39–1.83), fatigue (OR 1.56, 95% CI, 1.35–1.8), pain interfer-
ence (OR 1.84, 95% CI, 1.59–2.12), sleep disturbances (OR 1.61,
95% CI, 1.4–1.86), and decreased social satisfaction (OR 1.48,
95% CI, 1.29–1.70). Analyses were repeated within strata of dis-
ease activity, with similar results (Fig. 2).
DISCUSSION
In this large sample of self-reported patients with IBD, one
in every 5 participants had a concomitant IBS diagnosis. After sex
TABLE 1. Demographic and Disease-related Characteristics of Patients with IBD Stratified by Disease Subtype
and Concomitant IBS Diagnosis
Characteristics
CD (n ¼ 3947) UC/IC (n ¼ 2362)
IBD (n ¼ 3158) IBD/IBS (n ¼ 789) IBD (n ¼ 1872) IBD/IBS (n ¼ 490)
Age, yr 43.7 (15) 44 (16) 43.7 (15) 47 (16)
Female sex 71.2 78.3 69.3 75.5
Body mass index, kg/m2 25.5 (6) 26.2 (6) 25.6 (6) 26.4 (6)
Current smoker 2.4 3 1 2.7
Patients with college degree 72.8 65.3 76.7 71.1
Disease duration, yr 15.9 (14) 15.4 (13) 11.5 (11) 12.7 (12)
University-academic GI settings 22.8 22.6 19.2 16.6
History of $1 bowel surgery 53.3 47.9 15.5 10
Current ileal or Koch pouch 3 4 9.4 3.7
Current ostomy 10 6 4 2.5
sCDAI (CD) and SCCAI (UC/IC) 82 (34) 90 (35) 1.03 (0.8) 1.2 (0.8)
Proportion of patients who met the criteria of active diseasea 34.8 48.9 48.3 63.7
Data presented as mean (SD) and percentages.
aActive disease defined as sCDAI $150 for CD and SCCAI .2 for UC/IC.
adjustment, the IBS prevalence remained almost 75% higher than
the prevalence in the general US population, 19% versus 11%,
respectively. Contrary to the findings from several previous
studies, which suggested higher IBS prevalence in CD compared
with patients with UC, in our study, the prevalence was
comparable within the 2 disease subtypes.2,4,13,14,26,27 The differ-
ent epidemiologic distribution in our study may be related to the
distinct characteristics of the studied population. Our cohort is
internet based, with predominantly white females and may not
represent the general IBD population. Alternatively, the small
sample size in the previous studies may have influenced their
reported results. Regardless of the exact prevalence in each dis-
ease subtype, it remains evident that patients with IBD have con-
siderably higher prevalence of IBS compared with the general
population.
Several other important findings were observed in this
study. First, patients with IBD–IBS were more likely to have $5
annual office visits to their PCP and GI physicians compared with
those with no concomitant IBS diagnosis. This is consistent with
the pattern of resource utilization in the general IBS population as
IBS is estimated to be responsible;3.6 million physician visits in
the Unites States annually.28 Although clinic visits represent only
one indicator of the disease burden, those visits frequently gener-
ate a trail of health expenditures related to medication prescrip-
tions and diagnostic procedures/tests. Furthermore, it has been
previously shown that patients tend to underestimate the number
of physician office visits,29,30 hence, the burden may be even
higher.
The second important observation in this study is the noted
high rate of narcotic utilization in association with IBD–IBS. This
is of particular significance for patients with IBD as the use of
narcotic-based analgesia has been linked to a number of adverse
effects, including higher rate of infectious complications, surgical
complications, and even mortality.31–33 In a study by Long et al10
assessing risks of narcotic use in hospitalized patients with IBD,
all patients with previous IBD–IBS diagnosis received narcotic-
based analgesia during their hospitalization. Having CD, disease
duration, previous psychiatric comorbidities, outpatient narcotic
use, current smoking, and previous IBD-specific surgery were
also associated with narcotic use in hospitalized patients with
TABLE 2. Comparison of the Health Resources and Medication Utilization Between IBD Patients with and
Without Concomitant IBS Diagnosis Stratified by Disease Subtype
Characteristics
CD (n ¼ 3947) UC/IC (n ¼ 2362)
IBD (n ¼ 3158) IBD/IBS (n ¼ 789) Pa IBD (n ¼ 1872) IBD/IBS (n ¼ 490) P
Patients with $5 GI clinic visit
within the previous year
15.7 20.0 0.01 12 15 0.09
Patients with $5 PCP clinic visit
within the previous year
10.9 19.1 ,0.001 8.7 14.8 ,0.001
Narcotics 10.5 16.5 ,0.001 4.7 9.3 ,0.001
Corticosteroids 12.7 9 0.01 11.8 13.3 0.41
5-aminosalicylatesb 26.1 25.1 0.58 56.1 60.8 0.08
Immunomodulator 28.8 25.6 0.08 21.8 18.8 0.17
Biological therapyc 43 43 0.9 23 23.2 0.98
Data presented are percentages.
aComparisons were made using Pearson’s chi-square test for categorical variables.
bAzathioprine, 6-mercaptopurine, and methotrexate.
cAnti–tumor necrosis factor agents and antiadhesions (vedolizumab and natalizumab).
FIGURE 1. Rates of narcotics utilization among IBD patients with 
and without concomitant IBS diagnosis stratified by disease subtype 
and disease activity. *Clinical remission defined as sCDAI ,150 for 
CD and SCCAI #2 for UC/IC.
IBD. In the outpatient setting, several factors were linked to
increased narcotic use in patients with IBD, including psychiatric
comorbidities, female sex, history of abuse, and clinical disease
activity.34–36 However, the impact of IBD–IBS on outpatient nar-
cotic use has not been previously assessed. In our study, patients
with IBD–IBS had higher rates of narcotic use compared with
those with no IBS diagnosis. The differences in narcotic use
remained significant even after we excluded those who met clin-
ical criteria of active disease. Lastly, consistent with the previous
reports, IBD–IBS in our cohort was associated with reduced
HRQOL as measured by SIBDQ in both disease subtypes. More-
over, IBD–IBS diagnosis was found to be an independent pre-
dictor for all 6 PROs; anxiety, depression, fatigue, pain
interference, sleep disturbances, and reduced social satisfaction.
Those effects remain significant after we excluded patients who
met clinical criteria for active disease.
There are several strengths to this study. It is the largest
study to date that examines the prevalence and impacts of IBS
in patients with IBD. The large sample size allowed for data
stratification and separate analyses within disease subtypes. It
also allowed for adequate statistical power and meaningful
assessments of the different associations between IBD–IBS and
PROs while taking into account many of the confounding fac-
tors. The use of validated scales for the various PROs,
HRQOL, and self-reported measurement of disease activity is
another strength.
TABLE 3. Quality of Life Measures and PROs in IBD Patients with and Without IBS Diagnosis Stratified by Disease
Subtype
Outcome
CD (n ¼ 3947) UC/IC (n ¼ 2362)
IBD (n ¼ 3158) IBD/IBSa (n ¼ 789) IBD (n ¼ 1872) IBD/IBSa (n ¼ 490)
SIBDQb 5 (1) 4 (1) 5.2 (1) 4.7 (1)
Anxiety 51.9 (10) 54.7 (10) 51.3 (9) 54.3 (10)
Depression 50.3 (9) 52.7 (10) 49.4 (9) 52.2 (10)
Fatigue 54.7 (11) 57.6 (11) 52.4 (11) 55.8 (11)
Pain interference 51.2 (10) 54.4 (10) 49.8 (9) 54.5 (10)
Sleep disturbances 51.4 (8) 53.6 (9) 49.9 (8) 52.3 (8)
Social satisfaction 49.3 (10) 47.1 (10) 50.4 (10) 47.2 (10)
Data presented as mean (SD).
aFor every evaluated outcome, the mean value was significantly different for IBD–IBS compared with IBD with no IBS diagnosis. P value ,0.001 (Student’s t test).
bSIBDQ, short IBD questionnaire.
FIGURE 2. Impact of IBD–IBS on PROs. Data represent ORs and 95% CIs.
We also recognize a number of limitations to our study. First,
all data in our cohort are self-reported with inability to verify self-
reported information in each participant. Nevertheless, a recent
validation study revealed 97% accuracy rate of self-reported IBD
status and disease subtypes within the CCFA Partners cohort.37
Another limitation concerning the self-reported nature of the study
is the IBS diagnosis. In our cohort, patients with IBD–IBS were
identified on the basis of the participants’ report that they were told
they had IBS by their treating physician. Hence, the exact IBS
criteria used to confirm the diagnosis are unknown. In addition, it
is unclear whether other potential causes of the patient’s symptoms
were ruled out or treated before IBS diagnosis (e.g., small intestinal
bacterial overgrowth and celiac disease). Those uncertainties in the
diagnosis make this a potentially heterogeneous group of IBD pa-
tients with IBS-like symptoms rather than a unified cohort of pa-
tients with IBD–IBS. Another limitation to this study is the inability
to objectively confirm the presence and severity of active inflam-
mation. This is important as active disease can independently
impact the individual patient’s quality of life and functional status
and may be a source of bias in our analyses. In addition, the clinical
measures of disease activity, sCDAI and SCCAI, can be elevated in
patients with IBS who have no active inflammation. Hence, using
these indices to define clinical disease activity may result in mis-
classification of some patients with IBD–IBS. Nevertheless, con-
comitant IBS diagnosis remains a significant predictor for adverse
PROs even after excluding patients with significant GI symptoms
meeting the clinical criteria of active IBD suggesting that those
associations are true.
In conclusion, in this cross-sectional study of patients
with IBD, there was a high prevalence of coexisting IBS
diagnosis in both patients with CD and UC/IC. Furthermore,
concomitant IBS diagnosis was associated with high rates of
narcotic use, increased health resources utilization, lower
quality of life, and adverse PROs. As each of these influences
can negatively impact an IBD patient’s care, it is important to
identify patients with a concomitant IBS diagnosis and provide
the appropriate counseling and medical therapy.
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